Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 6/20 | 0.81 |
| ▸ | ALB | P02768 | 1/20 | 0.53 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | METAP2 | P50579 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21378631 | 0.90 | TTR (1.00) | TTRALBP2RX7MEN1KMT2A | |
| SCHEMBL26745347 | 0.82 | TTR (0.79) | TTRALBP2RX7L3MBTL1MEN1 | |
| SCHEMBL15816962 | 0.81 | TTR (1.00) | TTRALBMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL17522791 | 0.78 | TTR (0.94) | TTRALBMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL25311559 | 0.78 | TTR (0.77) | TTRALBP2RX7L3MBTL1MEN1 | |
| SCHEMBL29433285 | 0.77 | TTR (0.72) | TTRALBMEN1KMT2ANOTUM | |
| SCHEMBL25310955 | 0.77 | TTR (0.72) | TTRALBMEN1KMT2ANOTUM | |
| SCHEMBL29433284 | 0.77 | TTR (0.72) | TTRALBMEN1KMT2ANOTUM | |
| SCHEMBL26744821 | 0.76 | TTR (0.61) | TTRALBL3MBTL1NOTUMTDP1 | |
| SCHEMBL22132086 | 0.76 | TTR (0.73) | TTRALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250041276-A1 | METHODS OF TREATING TTR AMYLOIDOSIS USING AG10 | ALTER DOMUS (US) LLC, AS COLLATERAL AGENT | 2025-02-06 | — | — | US | disclosed |
| US-12070449-B2 | Methods of treating TTR amyloidosis using AG10 | Eidos Therapeutics, Inc. (US) | 2024-08-27 | — | — | US | disclosed |
| US-20220016081-A1 | METHODS OF TREATING TTR AMYLOIDOSIS USING AG10 | ADRENAS THERAPEUTICS INC. | 2022-01-20 | — | — | US | disclosed |
| US-11058668-B2 | Methods of treating TTR amyloidosis using AG10 | Eidos Therapeutics, Inc. (US) | 2021-07-13 | — | — | US | disclosed |
| CN-112218632-A | Methods of treating TTR amyloidosis with AG10 | 文涵治疗有限公司 | 2021-01-12 | — | — | CN | disclosed |
| US-20190290616-A1 | METHODS OF TREATING TTR AMYLOIDOSIS USING AG10 | QED THERAPEUTICS, INC. | 2019-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190290616-A1 | METHODS OF TREATING TTR AMYLOIDOSIS USING AG10 | TTR, TMSB10, APOB | TTR 1/4885ALB 4/4885P2RX7 4516/4885 |
| US-20250041276-A1 | METHODS OF TREATING TTR AMYLOIDOSIS USING AG10 | TTR, TMSB10, APOB | TTR 1/4885ALB 4/4885P2RX7 4516/4885 |
| US-12070449-B2 | Methods of treating TTR amyloidosis using AG10 | TTR, APOB, TMSB10 | TTR 1/4885ALB 4/4885P2RX7 4514/4885 |
| US-20220016081-A1 | METHODS OF TREATING TTR AMYLOIDOSIS USING AG10 | TTR, APOB, TMSB10 | TTR 1/4885ALB 4/4885P2RX7 4514/4885 |
| US-11058668-B2 | Methods of treating TTR amyloidosis using AG10 | TTR, TMSB10, APOB | TTR 1/4885ALB 4/4885P2RX7 4516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.